(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 104.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Zenas Biopharma's revenue in 2025 is $5,000,000.On average, 1 Wall Street analysts forecast ZBIO's revenue for 2025 to be $835,986,720, with the lowest ZBIO revenue forecast at $835,986,720, and the highest ZBIO revenue forecast at $835,986,720. On average, 2 Wall Street analysts forecast ZBIO's revenue for 2026 to be $2,134,692,090, with the lowest ZBIO revenue forecast at $716,440,619, and the highest ZBIO revenue forecast at $3,552,943,560.
In 2027, ZBIO is forecast to generate $1,611,364,403 in revenue, with the lowest revenue forecast at $1,433,717,225 and the highest revenue forecast at $1,924,023,436.